

Silva Pharmaceuticals Limited Utilization of IPO Fund Proceeds

For the month ended 31December 2023







AUDITORS' REPORT

on

Utilization of IPO Proceeds

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of Silva Pharmaceuticals Limited for the month ended 31 December 2023 as per required by Bangladesh Securities and Exchange Commission (BSEC) under Section 2CC of the Securities and Exchange Ordinance 1969.

Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June 2018 and other applicable laws and regulations.

Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 2, 3, 5 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations, gives a true and fair view of the statement for the month 31 December 2023.

As per TOR, we draw attention to the following matter:

1. During the month of December 2023, no expenses has been incurred in respect of Civil Construction. However, the company has utilized accumulative amount of Tk. 60,532,650 up to 31 December 2023 which was 104.26% of the amount specified in the prospectus and thereafter revised utilization plan for the purpose of Civil Construction. As such, approval was a prerequisite from the respected shareholders and concerned regulatory authority for the excess utilized amount of Tk. 2,474,124.







- 2. During the month of December 2023, no expenses has been incurred in respect of purchase of new Machinery and Equipment's. However, the company has utilized accumulative amount of Tk. 94,317,362 which was 76.99% up to 31 December 2023 in respect of Purchase of Machinery and Equipment's.
- 3. The Company has utilized Tk. 99,000,000 which was 100% of the budgeted amount up to 31 December 2023 for the purpose of loan repayment as specified in the prospectus.
- 4. The Company has utilized Tk. 20,441,474 which was 100% of the budgeted amount up to 31 December 2023 for the purpose of IPO expenses as specified in the prospectus and thereafter revised utilization plan.

We also state that:

- a) IPO proceeds have been utilized for the purposes as specified in the prospectus and thereafter revised utilization plan except the above said issues no.1 of the Company;
- b) IPO proceeds have been utilized in so far line with the conditions of the BSEC's consent letter for the IPO except the above said issues no. 1.
- c) The time frame for completion of the utilization of IPO proceeds was revised and will be completed within the time frame as specified in the resolution of 21st Annual General Meeting (AGM).
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the prospectus and 18th AGM of the Company.
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Mesbah Uddin FCA

Partner

ICAB Enroll no: 1533

Pinaki & Company Chartered Accountants

Dhaka, BangladeshDated: 04 January 2024



Remarks

23.01

(Amount in BDT)



9.39





Report on Utilization of IPO Proceeds For the Month of December 2023

Silva Pharmaceuticals Limited BDT 300,000,000 Amount (BDT) of capital raised through IPO:

Last Date of Full Utilization of IPO Fund as per Prospectus

Date of Close of Subscription:

Name of the Company:

Proceeds Receiving Date:

As stated in time line columns 10 October 2018 05 August 2018

Un -utilized 28,182,638 28,182,638 Total unutilized 0.82 Excess-utilized % 2,474,124 Excess Utilized Status of Utilization 104.26 91.43 100.00 100.00 Utilized % 60,532,650 99,000,000 20,441,474 Total Utilized 274,291,486 During the Month 60,532,650 94,317,362 99,000,000 20,441,474 274,291,486 Opening 4mount as per 18th AGM 300,000,000 58,058,526 99,000,000 20,441,474 122,500,000 per Prospectus 56,000,000 122,500,000 99,000,000 22,500,000 300,000,000 Amount as As per 21st AGM 31.12.2023 N/A N/A N/A As per 19th AGM 31.12.2022 31.12.2022 N/A N/A As per 18th AGM 09.10.2020 09.10.2020 N/A N/A 09.04.2020 09.04.2020 09.01.2019 As per N/A Purpose mentioned in the prospectus / 18th AGM Machinery and Equipment Borrowing at prospectus Repayment of Bank Civil Construction IPO Expenses

b) IPO proceeds have been utilized for the purposes/heads as secified in the propectus and in line with the condition of the Commission's consent letter.

1,048,326

27,756,122 53,414,637

26,707,796

Md. Abul Kasem

Chief Financial Officer

Januan Dr. Saira Khan Managing Director

Elvisa.

d) Un-Utilized IPO Proceeds with interest income in BDT -

c) Interest on IPO Proceeds in BDT (from FDR & SND) -

Add: Interest, net off tax, 13/06/2023 to 13/12/2023

a) Actual application was received almost 25.76 Times.

Silvana Mirza Chairman

Dhaka Dated : 04 January 2024